Tysabri 300 mg concentrate for solution for infusion

DRUG4 trials

Sponsors

Antwerp University Hospital, Helse Bergen HF, Amsterdam UMC Stichting, Fondazione Italiana Sclerosi Multipla Ente Del Terzo Settore/et S

Conditions

Multiple SclerosisMultiple sclerosisProgressive Multiple SclerosisRelapsing Remitting Multiple Sclerosis

Phase 2

Metformin add-on clinical study in multiple sclerosis to evaluate brain remyelination and neurodegeneration: a phase IIb triple-blind placebo-controlled randomized clinical trial (MACSiMiSE-BRAIN)

Active, not recruitingCTIS2023-503190-38-00

Antwerp University HospitalProgressive Multiple Sclerosis

Start: 2023-11-23Target: 120Updated: 2025-11-07

Tenofovir Alafenamide Fumarate and Epstein-Barr virus activity in people with MS – The TAF-MS study

CompletedCTIS2023-503814-62-00

Helse Bergen HFMultiple sclerosis

Start: 2024-02-06End: 2025-11-14Target: 50Updated: 2024-11-08

NO EVIDENCE OF DISEASE ACTIVITY AFTER AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN AGGRESSIVE MULTIPLE SCLEROSIS: THE NET-MS STUDY

RecruitingCTIS2024-515470-26-00

Fondazione Italiana Sclerosi Multipla Ente Del Terzo Settore/et SRelapsing Remitting Multiple Sclerosis

Start: 2024-10-31Target: 90Updated: 2025-11-17

Phase 4

Personalized extended interval dosing of natalizumab in relapsing remitting multiple sclerosis (NEXT-MS)

Not yet recruitingCTIS2024-513105-31-00

Amsterdam UMC StichtingMultiple Sclerosis

Target: 440Updated: 2024-07-30

Related Papers

A metformin add-on clinical study in multiple sclerosis to evaluate brain remyelination and neurodegeneration (MACSiMiSE-BRAIN): study protocol for a multi-center randomized placebo controlled clinical trial

Frontiers in Immunology2024-02-2123 citations